[Evaluation of the results of radiotherapy in planocellular bronchial carcinoma].
The analysis comprised 23 patients with planocellular bronchial carcinoma in whom monoradiotherapy was used. Stage III dominated in the studied group (56.6%). Positive response to therapy was achieved in 60.9% of the patients. The effect was maintained for 9 months and after that the disease continued to progress. In 17.4% of the patients the findings remained unchanged, while in 21.7% uninterrupted progression of the disease was noted. Therapeutical doses of 45 Gy and 60 Gy were applied in 52.2% and 47.8% patients, respectively. Survival of one year was achieved in 26.1% while 4.3% survived for two years. Advanced stage of the disease dominating in the studied group could be the reason for the low survival rate. The results presented as well as the referential ones suggest the better response to therapy and longer survival of patients with planocellular bronchial carcinoma in whom higher therapeutical irradiation dose was applied (60 Gy).
Nagorni-Obradović
L
L
Univerzitetski klinicki centar Institut za plućne bolesti i tuberkulozu Beograd.
D000328:Adult; D000368:Aged; D002283:Carcinoma, Bronchogenic / Q000401:mortality / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
Procena rezultata radioterapije planocelulnog karcinoma bronha.